Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients - A pilot study

Supportive Care in Cancer

Volumn 20, Issue 11, 2012, Pages 2713-2720

  Ferroni, Patrizia ^a   Martini, Francesca ^a   Portarena, Ilaria ^b   Grenga, Italia ^b   Riondino, Silvia ^a   La Farina, Francesca ^a   Laudisi, Anastasia ^b   Guadagni, Fiorella ^a   Roselli, Mario ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Activated proteinC; Cancer; Chemotherapy; Protac induced coagulation inhibition; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

APC PROTEIN; BEVACIZUMAB; BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID; ERYTHROPOIETIN; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; OUTPATIENTS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEIN C; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; SURVIVAL ANALYSIS; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 84868471444     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1391-1     Document Type: Article

References (37)

1. Haddad TC, Greeno EW(2006) Chemotherapy-induced thrombosis. Thromb Res 118(5):555-568
2. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27 (29):4839-4847
3. Di NisioM, Ferrante N, De TursiM, Iacobelli S, Cuccurullo F, Büller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104(5):1049-1054
4. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3):529-535
5. Feffer SE, Carmosino LS, Fox RL (1989) Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 63(7):1303-1307
6. Sousou T, Khorana AA (2009) New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 29(3):316-320
7. Ferroni P, Formica V, Roselli M, Guadagni F (2010) Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 8(1):102-113
8. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, on behalf of the PROTECHT Investigators (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943-949
9. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism. American College of Chest Physicians evidence-based clinical practice guidelines (8th edn.). Chest 133(6 Suppl):381S-453S
10. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490-5505
11. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27(29):4919-4926
12. Mandalà M, Falanga A, Roila F, On behalf of the ESMO Guidelines Working Group (2010) Venous thromboembolism in cancer patients: ESMO clinical practice guidelines for the management. Ann Oncol 21(Suppl 5):v274-v276
13. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902-4907
14. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112(7):2703-2708
15. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I (2009) D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27(25):4124-4129
16. Agterof MJ, van Bladel ER, Schutgens RE, Snijder RJ, Tromp EA, Prins MH, Biesma DH (2009) Risk stratification of patients with pulmonary embolismbased on pulse rate and D-dimer concentration. Thromb Haemost 102(4):683-687
17. Douma RA, van Sluis GL, Kamphuisen PW, SöhneM, Leebeek FW, Bossuyt PM, Büller HR (2010) Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 104(4):831-836
18. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Laudisi A, Roselli M, Guadagni F (2011) An APC-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb Haemost 105(5):931-932
19. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, Schirru M, Laudisi A, Roselli M, Guadagni F (2010) Association between increased tumor necrosis factor-alpha levels and impaired functionality of the protein C anticoagulant pathway in patients with metastatic colorectal cancer. Pathophysiol Haemost Thromb 37 (Suppl 1):A107
20. Elice F, Fink L, Tricot G, Barlogie B, Zangari M (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134(4):399-405
21. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I (2004) Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15 (11):1622-1626
22. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyllou K, Livadiotaki A, Kapsoritakis A, Lydataki N (2002) Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32(1):2-7
23. Negaard HF, Iversen PO, Østenstad B, Mowinckel MC, Sandset PM (2008) Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost 6(9):1482-1487
24. Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, Tripodi A (2009) A new chromogenic assay (HemosIL Thrombo- Path) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 124 (1):137-143
25. Lewis MR, Callas PW, Jenny NS, Tracy RP (2001) Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples. Thromb Haemost 86(6):1495-1500
26. Mandalà M, Barni S, Prins M, Labianca R, Tondini C, Russo L, Milesi A, Cremonesi M, Zaccanelli M, Regonesi C, Moro C, Falanga A (2010) Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 21(4):871-876
27. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377-5382
28. Lyman GH (2009) Thromboprophylaxis with low-molecularweight heparin in medical patients with cancer. Cancer 115 (24):5637-5650
29. Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, Kauschat-Brüning D, Bramlage P, Dörken B, Oettle H (2008) Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 8:361
30. Maraveyas A, Waters J, Roy R, Propper D, Fyfe D, Lofts F, Gardiner E, Sgouros J, Wedgwood K (2009) Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Eur J Cancer Suppl 7:362
31. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339-2346
32. Noble S (2009) A step in the right direction, but one size might not fit all. Lancet Oncol 10(10):930-931
33. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12(3):356-361
34. Pabinger I, Ay C (2009) Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 29(3):332-336
35. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, Zielinski C, Pabinger I (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29(15):2099-2103
36. Tripodi A, Legnani C, Lemma L, Cosmi B, Palareti G, Chantarangkul V, Mannucci PM (2010) Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 30 (2):215-219
37. Rectenwald JE, Myers DD Jr, Hawley AE, Longo C, Henke PK, Guire KE, Schmaier AH,Wakefield TW (2005) D-dimer, P-selectin, andmicroparticles: novelmarkers to predict deep venous thrombosis. A pilot study. Thromb Haemost 94(6):1312-1317